Premium
Belatacept conversion in an HIV ‐positive kidney transplant recipient following anti‐thymocyte globulin induction
Author(s) -
Kuten Samantha A.,
Patel Samir J.,
Baru Ashvin,
Gaber A. Osama,
Crutchley Rustin D.,
Ramanathan Venkataraman,
Knight Richard J.
Publication year - 2017
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.12748
Subject(s) - belatacept , anti thymocyte globulin , medicine , clearance , immunology , abatacept , kidney transplantation , immunosuppression , antibody , human immunodeficiency virus (hiv) , renal function , globulin , transplantation , virology , kidney transplant , urology , rituximab
Herein, we describe a case of early belatacept conversion in a human immunodeficiency virus ( HIV )‐positive kidney transplant recipient in an effort to improve suboptimal graft function and avoid drug interactions following anti‐thymocyte globulin ( ATG ) administration. We observed improvement in renal function without HIV disease progression or opportunistic infections. Donor‐specific antibodies appeared shortly after conversion but cleared without intervention. This case highlights belatacept as a means to improve renal function and avoid significant drug interactions even following ATG induction.